EPHX2 and obesity disorder: Notably, it is of critical importance to test whether it is feasible to target sEH for preventing or treating obesity-associated CRC, since the pharmacological inhibitors of sEH are currently being evaluated in multiple human clinical trials targeting other human disorders [10, 11], and these drugs could be repurposed for preventing or treating obesity-associated CRC.